

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement

A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly

The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*

A description of all covariates tested

A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons

A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)

For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*

For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings

For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes

Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection Data was collected from the Clalit Health Services operational database, using the institutional Business Objects system.

Data analysis R statistical software version 3.5.0 (R Foundation) was used for the univariate and multivariate survival analysis with time-dependent covariates. The following R packages were used: survival, foreign, ggplot2, ggrepify, ggpubr, survminer, gmodels and g summary. All R packages are freely available. SPSS software, version 26 (IBM), was utilized for all other statistical analyses.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Due the CHS data privacy regulations, and per the institutional Helsinki and data utilization committee approvals for the study, the patient-level data used for this study cannot be shared.

# Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences  Behavioural & social sciences  Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	All eligible subjects in Clalit Health Services were included in the study.
Data exclusions	The exclusion criteria included participants over the age of 100, participants with a documented previous SARS-CoV-2 infection, participants who received a first-booster dose less than four months before, or a second-booster before the study start date. To minimize calendar time bias, participants who became entitled to the second-booster during the study follow-up period were also excluded from the study. Since CHS started administering the mRNA-1273 (ModernaTX) vaccine in August 2021, primarily to patients who already had recovered from Covid-19, mRNA-1273 recipients were also excluded. Participants who received an oral anti-Covid-19 therapy (nirmatrelvir-ritonavir or molnupiravir) during the study period were also excluded.
Replication	Not relevant
Randomization	Not relevant- retrospective cohort study.
Blinding	Not relevant- retrospective cohort study.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems	Methods
n/a	Involved in the study
<input checked="" type="checkbox"/> <input type="checkbox"/> Antibodies	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/> <input type="checkbox"/> Eukaryotic cell lines	<input checked="" type="checkbox"/> <input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/> <input type="checkbox"/> Palaeontology and archaeology	<input checked="" type="checkbox"/> <input type="checkbox"/> MRI-based neuroimaging
<input checked="" type="checkbox"/> <input type="checkbox"/> Animals and other organisms	
<input type="checkbox"/> <input checked="" type="checkbox"/> Human research participants	
<input checked="" type="checkbox"/> <input type="checkbox"/> Clinical data	
<input checked="" type="checkbox"/> <input type="checkbox"/> Dual use research of concern	

## Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics	All eligible subjects in Clalit Health Services were included in the study.
Recruitment	Participants were not recruited: relevant participant data was extracted retrospectively from Clalit Health Services database.
Ethics oversight	The Clalit Health Services Helsinki and data utilization committees approved the study.

Note that full information on the approval of the study protocol must also be provided in the manuscript.